U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the ...
Company announcement – No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA concluded that Zealand Pharma’s application did not meet …